Posted by Michael Wonder on 26 Aug 2016
New Brunswick includes Lemtrada (alemtuzumab) on provincial drug program for eligible patients
25 August 2016 - Unique treatment delivered in only two cycles one year apart.
Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that the Government of New Brunswick has added Lemtrada (alemtuzumab) to the New Brunswick Prescription Drug Program through special authorization for eligible people living with relapsing-remitting multiple sclerosis.
New Brunswick joins a growing list of provinces, including Quebec, Saskatchewan, Manitoba and Ontario in making the unique treatment available to patients 18 years or older who meet specific criteria.
"We are very excited to see New Brunswick become the first Atlantic province to offer this treatment option to help people living with relapsing-remitting multiple sclerosis manage their disease," says Ben Davis, President of the MS Society of Canada, Atlantic Division.
